ANTX - CIK 0001880438
AN2 Therapeutics, Inc. (ANTX) reported net income of -$35.17M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$35.17M | +31.5% |
| FY 2024 | -$51.32M | +20.7% |
| FY 2023 | -$64.73M | -58.1% |
| FY 2022 | -$40.96M | -90.1% |
| FY 2021 | -$21.54M | - |
AN2 Therapeutics, Inc. (ANTX) reported net income of -$35.17M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2021 and fiscal 2025, AN2 Therapeutics, Inc.'s net income declined from -$21.54M to -$35.17M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.